A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 122, Issue 1, 2015, Pages 64-70

  Kisser, A ^a   Zechmeister Koss, I ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Cervical cancer screening; human papillomavirus; Ki 67; molecular diagnosis and prognosis; p16INK4A

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; P16 PROTEIN, HUMAN; TUMOR PROTEIN;

CANCER SCREENING; COLPOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; WART VIRUS; EARLY DIAGNOSIS; METABOLISM; PAPANICOLAOU TEST; PROGNOSIS; RISK ASSESSMENT; SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR;

ATYPICAL SQUAMOUS CELLS OF THE CERVIX; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM PROTEINS; PAPANICOLAOU TEST; PROGNOSIS; RISK ASSESSMENT; SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84920149226     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.13076     Document Type: Review

References (29)

1. Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R,. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev 2013; 2: 35.
2. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013; 17: S28-35.
3. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J,. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008; 111: 167-77.
4. Breitenecker G, Girardi F, Joura EA, Kohlberger P, Reich O, Widschwendter A, Hefler L, Kohlberger P, Reinthaller A,. Leitlinie für die Diagnose und Therapie von Cervikalen Intraepithelialen Neoplasien (CIN) und Mikrokarzinomen der Cervix uteri. Speculum Z Gynäkol Geburtshlf 2005; 23: 20-5.
5. AG-CPC-Arbeitsgemeinschaft für Zervixpathologie und Kolposkopie. Empfehlungen der AG-CPC zur Kolposkopie bei Erkrankungen des unteren Genitaltraktes der Frau. Dtsch Gesellsch Gynäkol Geburtshilfe. Cologne: AGCPC, 2008.
6. USPSTF. Screening for cervical cancer. 2012 [ http://uspreventivetaskforce.org/uspstf11/cervcancer/cervcancerrs.htm ]. Accessed 11 November 2013.
7. Flanagan SM, Wilson S, Luesley D, Damery SL, Greenfield SM,. Adverse outcomes after colposcopy. BMC Women's Health 2011; 11: 2.
8. Cardenas-Turanzas M, Follen M, Benedet JL, Cantor SB,. See-and-treat strategy for diagnosis and management of cervical squamous intraepithelial lesions. Lancet Oncol 2005; 6: 43-50.
9. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E,. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367: 489-98.
10. Sahasrabuddhe VV, Luhn P, Wentzensen N,. Human papillomavirus and cervical cancer: Biomarkers for improved prevention efforts. Future Microbiol 2011; 6: 1083-98.
11. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62: 147-72.
12. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003; 49: 7-18.
13. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-36.
14. Doebler P, Holling H,. Meta-analysis of Diagnostic Accuracy with mada. 2012 [ http://cran.r-project.org/web/packages/mada/vignettes/mada.pdf ]. Accessed 31 October 2013.
15. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383-94.
16. Singh S, Chang SM, Matchar DB, Bass EB,. Grading a body of evidence on diagnostic tests. In:, Chang SM, Matchar DB, Smetana GW, Umscheid CA, editors. Methods Guide for Medical Test Reviews. Rockville: Agency for Healthcare Research and Quality; 2012. pp. 7.1-7.13.
17. Merlin T, Weston A, Tooher R,. Extending an evidence hierarchy to include topics other than treatment: revising the Australian 'levels of evidence'. BMC Med Res Methodol 2009; 9: 34.
18. OCEBM Levels of Evidence Working Group, Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberat A, Moschetti I, Phillips B, Thornton H, Goddard O, Hodgkinson M,. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. [ http://www.cebm.net/index.aspx?o=5653 ]. Accessed 31 October 2013.
19. Ziemke P,. Immunocytochemistry (p16) as an additional examination for cytological specimens Class III D (Munich Classification II). Zentralbl Gynakol 2005; 127: 140-5.
20. Byun SW, Lee A, Kim S, Choi YJ, Lee YS, Park JS,. Immunostaining of p16(INK4a)/Ki-67 and L1 capsid protein on liquid-based cytology specimens obtained from ASC-H and LSIL-H cases. Int J Med Sci 2013; 10: 1602-7.
21. Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res 2012; 18: 4154-62.
22. Schmidt D, Bergeron C, Denton KJ, Ridder R, European CINtec Cytology Study Group. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011; 119: 158-66.
23. Waldstrom M, Christensen RK, Ornskov D,. Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion. Cancer Cytopathol 2013; 121: 136-45.
24. Loghavi S, Walts AE, Bose S,. CINtec(R) plus dual immunostain: a triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion. Diagn Cytopathol 2013; 41: 582-7.
25. Edgerton N, Cohen C, Siddiqui MT,. Evaluation of CINtec PLUS testing as an adjunctive test in ASC-US diagnosed SurePath preparations. Diagn Cytopathol 2013; 41: 35-40.
26. Lord SJ, Irwig L, Simes RJ,. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med 2006; 144: 850-5.
27. Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105: 1550-7.
28. Marquardt K, Buttner HH, Broschewitz U, Barten M, Schneider V,. Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause. Acta Cytol 2011; 55: 433-7.
29. Rasky E, Regitnig P, Schenouda M, Burkert N, Freidl W,. Quality of screening with conventional Pap smear in Austria-a longitudinal evaluation. BMC Public Health 2013; 13: 998.